-
Advaxis Kick Starts Early-Stage Study For Prostate Cancer Immunotherapy
Thursday, July 15, 2021 - 8:53am | 195Read More...Advaxis Inc (NASDAQ: ADXS) has initiated a Phase 1 study evaluating ADXS-504 in patients with recurrent prostate cancer. The study, being conducted at Columbia University Irving Medical Center, is the first clinical evaluation of ADXS-504, Advaxis' off-the-shelf neoantigen...
-
Harpoon Therapeutics Stock Drops After Prostate Cancer Candidate Shows Cytokine-Related Adverse Events
Friday, June 4, 2021 - 10:44am | 291Read More...Harpoon Therapeutics Inc (NASDAQ: HARP) has announced interim data from the ongoing dose-escalation portion of a Phase 1/2a trial evaluating HPN424 in patients with metastatic castration-resistant prostate cancer (mCRPC). Data were presented at the 2021 American Society of Clinical...
-
Bayer Buys Two Biotech Firms to Beef Up Radiopharmaceuticals
Thursday, June 3, 2021 - 3:25pm | 183Read More...Bayer AG (OTC: BAYRY) will acquire two small biotech companies in a deal that adds an experimental prostate cancer medicine to the German drugmaker's pipeline. Bayer will pay an undisclosed sum for Noria Therapeutics and PSMA Therapeutics, built around radiotherapy research from...
-
Novartis' Prostate Cancer Radioligand Therapy Extended Overall Survival by Four Months
Thursday, June 3, 2021 - 3:21pm | 253Read More...Novartis AG (NYSE: NVS) has announced results from Phase 3 VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC) in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Novartis said it...
-
Lantheus Shares Trading Higher On FDA Approval For Imaging Agent For Identification Of Prostate Cancer
Thursday, May 27, 2021 - 8:54am | 226Read More...The FDA has approved Lantheus Holdings Inc's (NASDAQ: LNTH) Pylarify, a positron emission tomography (PET) imaging agent, to identify suspected metastasis or recurrence of prostate cancer. Pylarify is an F 18-labeled prostate-specific membrane antigen (PSMA) imaging agent...
-
Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients
Tuesday, May 25, 2021 - 7:48am | 262Read More...Exelixis Inc (NASDAQ: EXEL) has announced results from cohort 6 of the COSMIC-021 Phase 1b trial evaluating Cabometyx (cabozantinib) in combination with Roche's Tecentriq (atezolizumab) in patients with locally advanced or metastatic solid tumors. Cohort...
-
ImmunityBio's Prostate Cancer Vaccine Shows Early Signs Of Clinical Activity, Durable Stable Disease
Monday, March 29, 2021 - 10:34am | 366Read More...ImmunityBio Inc (NASDAQ: IBRX) has announced the publication of Phase 1 study data of its Ad5 PSA/MUC-1/ brachyury-based immunotherapy vaccine for metastatic castration-resistant prostate cancer. Journal of ImmunoTherapy of Cancer (JITC) published the data. ...
-
Novartis' Radioligand Therapy Hits Primary Endpoint Goal In Prostate Cancer Study
Tuesday, March 23, 2021 - 9:52am | 225Read More...Novartis AG (NYSE: NVS) says that its Phase 3 VISION study of 177Lu-PSMA-617 hit both co-primary endpoints on overall survival and radiographic progression-free survival for prostate cancer patients. Details were not disclosed. Investigators tried to treat progressive PSMA-...
-
Cardiff Oncology's Onvansertib Combo Associated With Two-Fold Increase Disease Control Rate In Prostate Cancer Study
Thursday, February 11, 2021 - 12:11pm | 317Read More...Cardiff Oncology Inc (NASDAQ: CRDF) has announced updated data from its Phase 2 trial evaluating the oral combination of onvansertib, Johnson & Johnson's (NYSE: JNJ) Zytiga (abiraterone), and prednisone for metastatic castrate-resistant prostate...
-
Janssen's Erleada Plus, Zytiga Plus Prednisone Combo Treatment Shows Clinical Benefit In Late-Stage Prostate Cancer Study
Tuesday, February 9, 2021 - 6:43am | 329Read More...Johnson & Johnson’s (NYSE: JNJ) unit Janssen Pharmaceutical has announced results from Phase 3 ACIS study, evaluating the efficacy and safety of Erleada (apalutamide) and Zytiga (abiraterone) plus prednisone (treatment arm) compared to placebo and...
-
Poseida Shares Tank 34.5% As Prostate Cancer Drug Trial Halted After Patient's Death
Monday, August 17, 2020 - 11:33pm | 256Read More...Poseida Therapeutics Inc. (NASDAQ: PSTX) stock dropped about 34.5% in the after-hours trading on Monday, after a patient died in a prostate cancer drug trial, according to a filing the company made with the United States Securities and Exchange Commission. What Happened The trial was carried out in...
-
AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis
Tuesday, August 13, 2019 - 10:58am | 390Read More...Positive top-line results from a competitor’s prostate cancer drug trial led Bank of America to downgrade Clovis Oncology Inc (NASDAQ: CLVS). The Analyst Bank of America's Tazeen Ahmad downgraded Clovis Oncology from Buy to Neutral while lowering the price target from $13 to $7. The...
-
Medivation Up As Triple M&A Interest Rumor Circulates
Tuesday, March 22, 2016 - 11:47am | 292Read More...Medivation Inc (NASDAQ: MDVN) is up roughly 2 percent on Tuesday, trading at $37.68. According to the UK's financial outlet This Is Money, Medivation may be courting suitors. Among the names that have begun circulating as interested parties are AstraZeneca plc (ADR) (NYSE: AZN), Sanofi SA (ADR) (...
-
EXCLUSIVE: VolitionRX's New Cancer Diagnostic Could Mean No More Invasive Colonoscopies
Wednesday, March 11, 2015 - 12:30pm | 1549Read More...Uncomfortable and invasive colonoscopies might be a thing of the past with VolitionRX Ltd's (NYSE: VNRX) new cancer detection system. Through its research, VolitionRX developed a method for testing blood samples to detect various types of cancer, making diagnosis more accurate and reliable...
-
Dendreon CEO On The Life-Extending Effects Of Provenge (DNDN)
Monday, March 14, 2011 - 11:16am | 112Read More...Dendreon Corp. (DNDN) CEO Mitch Gold was on CNBC this morning to discuss the success and prospects of Provenge, a cellular immunotherapy that stimulates a patient's immune system to target and attack prostate cancer. “We've been fighting the war on cancer for 40 years,” Gold said. However, Dendreon...
